The Transcriptional Activator PAX3–FKHR
Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press The transcriptional activator PAX3–FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo Frédéric Relaix,1 Mariarosa Polimeni,2 Didier Rocancourt,1 Carola Ponzetto,3 Beat W. Schäfer,4 and Margaret Buckingham1,5 1CNRS URA 2375, Department of Developmental Biology, Pasteur Institute, 75724 Paris Cedex 15, France; 2Department of Experimental Medicine, Section of Anatomy, University of Pavia, 27100 Pavia, Italy; 3Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, 10126 Turin, Italy; 4Division of Clinical Chemistry and Biochemistry, Department of Pediatrics, University of Zurich, CH-8032 Zurich, Switzerland Pax3 is a key transcription factor implicated in development and human disease. To dissect the role of Pax3 in myogenesis and establish whether it is a repressor or activator, we generated loss- and gain-of-function alleles by targeting an nLacZ reporter and a sequence encoding the oncogenic fusion protein PAX3–FKHR into the Pax3 locus. Rescue of the Pax3 mutant phenotypes by PAX3–FKHR suggests that Pax3 acts as a transcriptional activator during embryogenesis. This is confirmed by a Pax reporter mouse. However, mice expressing PAX3–FKHR display developmental defects, including ectopic delamination and inappropriate migration of muscle precursor cells. These events result from overexpression of c-met, leading to constitutive activation of Met signaling, despite the absence of the ligand SF/HGF. Haploinsufficiency of c-met rescues this phenotype, confirming the direct genetic link with Pax3. The gain-of-function phenotype is also characterized by overactivation of MyoD.
[Show full text]